Indolmycin (TAK-083) is an antibiotic that acts as a competitive inhibitor of prokaryotic tryptophan-tRNA synthetase (TrpS); it exhibits antibacterial and antiviral activities; it shows bacteriostatic effects in vitro with good activity against MSSA (methicillin-susceptible Staphylococcus aureus), MRSA (methicillin-resistant S. aureus), and VISA (vancomycin-intermediate S. aureus), including strains resistant to mupirocin or fusidic acid.